Archive forDecember, 2006

Bipolar Disorder is Topic at NAMI Meeting 

Bipolar Disorder is Topic at NAMI Meeting 
By Victoria Advocate, Texas Nov. 11–Susan Satava on Monday will discuss bipolar disorder, and why — like diabetes and heart disease — the disorder is a long-term illness that must be carefully managed throughout your life.

Comments

Bristol-Myers bipolar therapy delays relapse

Bristol-Myers bipolar therapy delays relapse
Pharmaceutical Business Review - Dec 8, 2006… with Bristol-Myers Squibb and Otsuka Pharmaceuticals’ antipsychotic Abilify significantly delayed time to relapse in adults with bipolar disorder according to …

Comments

Depression (Bipolar Disorder)

Depression (Bipolar Disorder)
HealthCentral.com - Depression is a medical disorder characterized by feelings of sadness, hopelessness, pessimism, and a general loss of interest in life, combined with a sense of reduced emotional well-being. Major depression is manifested by a combination of symptoms …

Comments

Defendant in traffic death is bipolar, psychiatrist testifies 

Defendant in traffic death is bipolar, psychiatrist testifies 
WAUKESHA - A psychiatrist who has treated Howard Heinen Jr. told a jury Tuesday that his bipolar condition is such that “rational thinking usually goes out the window” when he is in his manic phase, which the defense suggests was the case when Heinen struck and killed a motorcyclist in Waukesha last fall.

Comments

Real hope of curing bipolar 

Real hope of curing bipolar 
THE decision to form a national research body to investigate finding a cure for schizophrenia and bipolar disease is a tremendous step forward for millions of people around the world.

Comments

Bolder II study: Quetiapine is an effective monotherapy for …

Bolder II study: Quetiapine is an effective monotherapy for …
Xagena.it, Italy - Dec 13, 2006Results from the BOLDER II ( BipOLar DepRession ) study confirm that Quetiapine ( Seroquel ) has the potential as a single medication to treat for major …

Comments

Memory Pharmaceuticals Earns Milestone Payment For Phase 2a Trial Of MEM 1003 In Bipolar Disorder 

Memory Pharmaceuticals Earns Milestone Payment For Phase 2a Trial Of MEM 1003 In Bipolar Disorder 
Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today announced that it had earned a milestone payment of $960,000 from the Stanley Medical Research Institute (SMRI) related to the ongoing Phase 2a trial of MEM 1003 in patients with acute mania in bipolar disorder. [click link for full article]

Comments

Bipolar disease a stealthy killer

Bipolar disease a stealthy killer
Reading Eagle, PA - 23 hours ago… wife. Kristine had bipolar disease, and she was ashamed of it. Bipolar disease is caused by an imbalance of chemicals in the brain. …

Comments

Eli Lilly’s response about Zyprexa for schizophrenia and bipolar …

Eli Lilly’s response about Zyprexa for schizophrenia and bipolar …
SpiritIndia, India - 15 hours ago… Lilly works to bring Zyprexa to physicians who are confronted with the need to diagnose and treat serious schizophrenia and bipolar disorder wherever they …

Comments

Eli Lilly’s response about Zyprexa for schizophrenia and bipolar …

Eli Lilly’s response about Zyprexa for schizophrenia and bipolar …
SpiritIndia, India - Dec 18, 2006… Lilly works to bring Zyprexa to physicians who are confronted with the need to diagnose and treat serious schizophrenia and bipolar disorder wherever they …

Comments

Next entries » · « Previous entries